Indication

Biallelic RPE65 mutation-associated retinal dystrophy

Biallelic RPE65 mutation-associated retinal dystrophy is a rare, severe inherited retinal disease characterized by pathogenic variants in both alleles of the *RPE65* gene. Read more about Biallelic RPE65 mutation-associated retinal dystrophy

1 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common Biallelic RPE65 mutation-associated retinal dystrophy therapies.

Showing 1–1 of 1 drugs

Filter & compare in the drug finder →Opens the drug finder with Biallelic RPE65 mutation-associated retinal dystrophy preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Biallelic RPE65 mutation-associated retinal dystrophy.

Biallelic RPE65 mutation-associated retinal dystrophy is a rare, severe inherited retinal disease characterized by pathogenic variants in both alleles of the *RPE65* gene.

This genetic defect disrupts the visual cycle in the retinal pigment epithelium by impairing the isomerohydrolase enzyme needed to convert all-*trans*-retinyl esters into 11-*cis*-retinal, ultimately causing progressive photoreceptor degeneration.

Clinically encompassing phenotypes such as Leber congenital amaurosis and early-onset retinitis pigmentosa, it primarily presents in infancy or early childhood with severe nyctalopia, nystagmus, and constricted visual fields.

Over time, affected individuals experience progressive peripheral and central vision loss, which typically leads to complete blindness as viable retinal tissue deteriorates.

Personalize your experience

Follow Biallelic RPE65 mutation-associated retinal dystrophy and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it